Reference
Huang Y-H, et al. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma. Cancer Research and Treatment 54: 434-444, No. 2, Apr 2022. Available from: URL: http://e-crt.org/journal/view.php?doi=10.4143/crt.2021.671
Rights and permissions
About this article
Cite this article
Afatinib/bevacizumab/erlotinib. Reactions Weekly 1952, 32 (2023). https://doi.org/10.1007/s40278-023-37125-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-37125-1